DermTech, Inc. (DMTKQ)
| Market Cap | 35.00 |
| Revenue (ttm) | 15.66M |
| Net Income (ttm) | -89.63M |
| Shares Out | 35.26M |
| EPS (ttm) | -2.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,050 |
| Average Volume | 8,089 |
| Open | 0.0001 |
| Previous Close | 0.0001 |
| Day's Range | 0.0001 - 0.0001 |
| 52-Week Range | n/a |
| Beta | 25.98 |
| RSI | 38.84 |
| Earnings Date | Aug 1, 2025 |
About DermTech
DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it ... [Read more]
Financial Performance
In 2023, DermTech's revenue was $15.30 million, an increase of 5.36% compared to the previous year's $14.52 million. Losses were -$100.89 million, -13.54% less than in 2022.
Financial StatementsNews
DERMTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating DermTech, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against DermTech, Inc. (OTC: DMTKQ) on b...
DermTech Completes Transaction for Asset Sale; Operations Continue Under New Ownership and Management
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (OTC: DMTKQ) (DermTech or the Company) a leader in precision dermatology offering non-invasive skin genomics solutions, today announced that it has closed it...